Compare NEO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | MNKD |
|---|---|---|
| Founded | 2001 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2008 | 2004 |
| Metric | NEO | MNKD |
|---|---|---|
| Price | $15.11 | $4.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $13.38 | $8.69 |
| AVG Volume (30 Days) | 3.4M | ★ 4.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $10.63 | $35.81 |
| Revenue Next Year | $9.73 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $4.72 | $2.23 |
| 52 Week High | $15.56 | $6.51 |
| Indicator | NEO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 83.10 | 69.91 |
| Support Level | $11.49 | $3.77 |
| Resistance Level | N/A | $6.12 |
| Average True Range (ATR) | 0.70 | 0.22 |
| MACD | 0.33 | 0.03 |
| Stochastic Oscillator | 92.82 | 97.24 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.